Fierce Pharma March 27, 2024
Angus Liu

As geopolitical tensions threaten to disrupt pharmaceutical supply chains, AstraZeneca is making plans to manufacture drugs for the U.S. and China markets independently from one another.

“We have a very large supply chain, and we are organizing ourselves so that we can actually supply the United States and Europe independently,” AstraZeneca CEO said in an interview with Bloomberg on the sidelines of the Boao Forum for Asia in China. “And we also are building our presence here in China, so we can actually supply Chinese patients independently.”

Soriot pointed to AZ’s recently announced $300 million cell therapy facility in Rockville, Maryland, following the company’s $1 billion acquisition of Chinese CAR-T biotech Gracell Biotechnologies.

“The fact that a product is invented...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma, Pharma / Biotech, Supply Chain, Technology
Mark Cuban: A Master Disrupter for American Healthcare
Despite Trump’s Tough Talk On PBMs, GOP House Lets Them Off The Hook
How has U.S. Spending on Health Care Changed Over Time?
Bringing genomics closer to patients: 3 takeaways from Henry Ford Health
Merck enters $2B licensing deal for weight loss drug

Share This Article